Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPOINT-PNH study of oral iptacopan in complement inhibitor-naive adult PNH patients
jRCT2051210047Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Proportion of participants achieving a sustained increase in hemoglobin levels of at least 2 g/dL in the absence of red blood cell transfusion. Started Apr 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2051210047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210047.